Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38593393/
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer
Experts suggest that neoadjuvant immune checkpoint therapy should not be offered outside of a trial setting until it becomes clear that this treatment strategy reduces risk of recurrence.
-
Albert Dekker1yrblack magic; still nobody appears to be able to identify those who will benefit
Clinical Factors Associated With Patterns of Endocrine Therapy Adherence in Premenopausal Breast Cancer Patients
Source : https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01819-4
Introduction Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is often suboptimal. We investigated longitudinal trends...
Women with stage I disease, without chemotherapy, with prevalent comorbid disease, and with a history of chronic noncancer medication use were more likely to be rapid decliners compared with high adherers.
-
Albert Dekker1yrIt makes sense but encouragement will unlikely to work as patients concentrate on other likely more dangerous and life limiting diseases
The USPSTF updated its recommendations for the screening of breast cancer in cisgender women and those assigned female sex at birth aged ≥40 years with average risk.
-
Albert Dekker1yrdense breast tissue is an issue of its own; one of the problems with US it is good Diagnostic tool but not screening tool
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response
Source : https://pubmed.ncbi.nlm.nih.gov/38569132/
pCR should be integrated with other prognostic factors to optimize postneoadjuvant treatments in BC.
Although it is associated with a common excellent prognosis, partial CR after neoadjuvant therapy for breast cancer does not fully depict patient outcomes.
-
Albert Dekker1yrvery challenging situation with few clinical trials these days having enough arms to thorough evaluate benefits of different treatment options or no treatment at all
Factors Associated With Overall Survival in Breast Cancer Patients With Leptomeningeal Disease (LMD): a Single Institutional Retrospective Review
Source : https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01789-7
Background Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5-8% of patients with breast cancer (BC). We conducted a retrospective review of BC-LMD patients diagnosed at Moffitt Cancer...
Systemic therapy, intrathecal therapy, and whole-body radiotherapy was associated with prolonged survival for all patients.
-
Albert Dekker1yrUnfortunately, terribly frequently end stage disease